2023-06-26 08:22:19 ET
- Avalo Therapeutics ( AVTX ) -89% announces topline data from phase 2 PEAK trial for AVTX-002 (quisovalimab) in patients with non-eosinophilic asthma.
- FibroGen ( FGEN ) -76% late-stage trial for lung disease candidate fails .
- Lulu's Fashion Lounge Holdings ( LVLU ) -20% .
- Mercury Systems ( MRCY ) -14% downgraded to Neutral at JPMorgan after not finding buyer .
- SAI.TECH Global Corporation ( SAI ) -11% .
- Argo Blockchain ( ARBK ) -9% .
- Hongli Group ( HLP ) -6% .
- AMTD Digital ( HKD ) -6% .
- Nauticus Robotics ( KITT ) -6%.
For further details see:
AVTX, ARBK and HKD among pre-market losers